Unfazed by disruptions, Cowen's investment arm backs AM-Pharma's $176M pivotal plan around lethal condition
It may not be the best time to start up a late-stage study unrelated to Covid-19, but AM-Pharma isn’t letting a slight delay derail its overall plan.
The Dutch biotech has been singularly focused on recAP, an anti-inflammatory recombinant human form of an enzyme originally found in cows called alkaline phosphatase.
The one Phase III it believes it needs for approval was scheduled for this summer, funded by a $133 million round last July. Having pushed study initiation to after the summer, AM-Pharma is adding $52 million for the regulatory work needed to prepare for launch, including CMC validation and commercial supply.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
